Riggs Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Riggs Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-28	Closed	-$3K	–	329
2021 Q1	$3K	Buy	+28	New	+$4.06K	﹤0.01%	262

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Riggs Asset Management's VYNE Position: Q2 2021 in Review

Riggs Asset Management sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 28 shares — an estimated $3K sold.

Riggs Asset Management first reported a position in VYNE in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

Riggs Asset Management reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
Riggs Asset Management sold 28 VYNE Therapeutics shares in Q2 2021, an estimated $3K.
Riggs Asset Management first reported a position in VYNE Therapeutics in Q1 2021 and held it in 1 quarter.
Riggs Asset Management's VYNE Therapeutics position peaked at $3K in Q1 2021.
72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Riggs Asset Management's 13F filing for Q2 2021, filed 16 Jul 2021.